At its meeting on 24 June 2024, the Transparency Council adopted position No. 60/2024 on the evaluation of the drug Acarizax (standardized allergen extract of house dust mites [Dermatophagoides pteronyssinus, Dermatophagoides farina]) for the indication of allergic rhinitis rhinitis and bronchial asthma accompanied by allergic rhinitis.